Dr. Eva Feldman was awarded an NIH grant (U24DK115255) as part of DiaComp to study oxidative stress in neuropathy. The goal is to gain a better understanding of NOX5-derived free radicals to support our efforts to develop and validate novel therapies that prevent nerve damage in diabetes, prediabetes, and obesity.
Prediabetic, diabetic, and obese individuals frequently develop neuropathy, i.e., nerve damage, but the mechanisms are not fully understood. Moreover, there are no treatments available to prevent or slow the progression of neuropathy. Oxidative stress, the presence of damaging “free radicals”, is one potential route of nerve damage. This grant will examine the contribution of an enzyme called NOX5 to free radicals in neuropathy, which could serve as a potential drug target.